AngioDynamics (ANGO) Tops Q2 EPS by 3c, Revenues Beat; Offers FY21 EPS/Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
AngioDynamics Reports Fiscal 2021 Second Quarter Financial Results
January 7, 2021 7:00 AM ESTFiscal 2021 Second Quarter Highlights
Net sales of $72.8 million increased 4.0% compared to the prior-year quarter Gross margin declined 410 basis points year over year to 55.2% GAAP loss per share of $0.11 and adjusted earnings per share of $0.01 Cash and cash equivalents on November 30, 2020 were $58.0 million, compared to $47.9 million on August 31, 2020 The Company reaffirms its guidance of fiscal year 2021 net sales between $278 and $284 million and fiscal year 2021 adjusted earnings per share between $0.00 and $0.05... More